Compare Ascendis Pharma A/S (ASND) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vipshop Holdings Ltd - ADR — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Vipshop Holdings Ltd - ADR trades at $14.07 (market cap $6.69B). The key difference: Ascendis Pharma A/S is far larger — about 2.7× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.45% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VIPS | |
|---|---|---|
Market Cap | $17.74B | $6.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $20.68 |
52-Week Low | $163.32 | $12.92 |
Enterprise Value | $18.11B | $3.29B |
Dividend Yield | — | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Vipshop Holdings (VIPS) trades at $13.94, up 0.65% with a bullish technical signal despite mixed earnings history. The stock shows attractive valuation metrics with P/E of 6.36 and P/S of 0.45, supported by solid profitability including 18.43% ROE. Recent Q1 2026 earnings matched expectations while the company pursues growth through outlet store strategies.
The outlook remains positive with analyst consensus favoring Buy ratings (53.57%) and improving cash flow trends. Key risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds, but strong fundamentals and institutional support suggest potential for upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
